Proof Of Concept Menstrual Hygiene Product-Wondaleaf®
Proof of Concept Study of Wondaleaf® As an Alternative to Menstrual Hygiene Product for Night Use Among Menstruating Women
1 other identifier
interventional
36
1 country
1
Brief Summary
General objective: To assess the preference and performance in terms of satisfaction and acceptability as well as safety profile of a novel innovative design of menstrual hygiene device (Wondaleaf®) during the night for menstruating women by comparing it to prior experience of the usual hygienic product for menstrual control, i.e. sanitary pads. Specific objectives:
- To determine the preference of participants between Wondaleaf® and usual sanitary pads as a night use menstrual hygiene product.
- To determine the satisfaction of participants towards Wondaleaf® and usual sanitary pads as a night use menstrual hygiene product.
- To determine the acceptability of participants towards Wondaleaf® as a night use menstrual hygiene product.
- To determine the safety profile of the Wondaleaf®.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2016
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2016
CompletedFirst Submitted
Initial submission to the registry
August 2, 2016
CompletedFirst Posted
Study publicly available on registry
August 5, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedFebruary 3, 2017
February 1, 2017
5 months
August 2, 2016
February 1, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Preference
Wondaleaf® usage during the night is better; same or worse as compared to usual sanitary pad usage during menstruation.
every night for one cycle of menstruation, an average of 5 days
Secondary Outcomes (3)
Satisfaction
every night for one cycle of menstruation, an average of 5 days
Acceptability
every night for one cycle of menstruation, an average of 5 days
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
every night for one cycle of menstruation till 3 months after last usage of investigational device
Study Arms (1)
Wondaleaf®
EXPERIMENTALThis is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
Interventions
Use of Wondaleaf® during menstruation every night in one menstrual cycle.
Eligibility Criteria
You may qualify if:
- Women within ages of 18 to 45 years old with good health and regular menstrual cycles with last menstrual cycle occurred within 5 weeks of enrolment; subjects can be rescreened after completion of menstrual cycle
- Women who use sanitary pads as their only menstrual hygiene product.
- Women who agree to use only the study menstrual hygiene device and not sanitary pads or other menstrual hygiene products for menstruation during the night time of study duration.
- Women who are able to understand instructions for correct use of study menstrual hygiene product (i.e. the investigational device).
- Literate women who can complete the study questionnaire on their own in a language of their choice which are English, Malay and Chinese; and attending all study visits.
You may not qualify if:
- Known history of vaginal or uterine infection(s), and/or urinary tract infections; these subjects can be rescreened after 14 days after successful treatment.
- Ongoing or past history of sexually transmitted disease, pelvic inflammatory disease, and/or injuries to the pelvis requiring surgical intervention and/or pelvic floor physiotherapy.
- Female subject who is pregnant (established by urinary pregnancy test).
- Sensitivity or allergy to polyurethane and acrylic adhesive hypoallergenic.
- Staff who work directly under the investigators and/or employed directly by the device manufacturers, sponsor and study team.
- Moving outside Sibu area during study period and have difficulty to return for Visit 2.
- Female subjects who have menopause (absence of menstruation for more than 6 months in female) or any other circumstances that cause secondary amenorrhea (absence of menstruation for more than 6 months in a normal female of reproductive age that is not due to pregnancy) such as side effect from hormonal contraceptive.
- Use any medications or preparation applied topically to the perineum or intravaginally to the genitalia but subjects can be rescreened 14 days after the recovery if the application is for acute illness.
- Use of any medications which known to influence menstruation or study results for any reasons within 14 days, 30 days before Visit 1 and during the intended study duration.
- Subject participating in another clinical study involving menstrual hygiene device.
- Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Fever is defined as axillary / tympanic / rectal temperature ≥ 38°C. Subjects can be rescreened 14 days after the recovery;
- Blood dyscrasias, bleeding disorder, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems;
- Presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous system(s) or psychiatric disease or other conditions that may interfere with the health conditions (such as in case the women subject become pregnant), or would place the subjects at increased risk, as determined by the investigator(s).
- Significant is defined as any disease/condition that, in the opinion of the researcher, would put the subject's safety at risk through study participation, or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Clinical Research Centre, Malaysialead
- Twin Catalyst Sdn. Bhd.collaborator
Study Sites (1)
Sibu Hospital
Sibu, Sarawak, 96000, Malaysia
Study Officials
- PRINCIPAL INVESTIGATOR
Teck Hock Toh
Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia
- PRINCIPAL INVESTIGATOR
Vivian Wee Yen Tan
Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 2, 2016
First Posted
August 5, 2016
Study Start
May 1, 2016
Primary Completion
October 1, 2016
Study Completion
December 1, 2016
Last Updated
February 3, 2017
Record last verified: 2017-02